FDA Inspection
Regeneron Pharmaceuticals IncRegeneron Pharmaceuticals Inc – FDA Inspection, Oct 18, 2019
Record Details
This FDA Inspection record concerns Regeneron Pharmaceuticals Inc, with an inspection on October 18, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- October 18, 2019
- Product Type
- Drugs
View Company Profile
ID · 2d3aca16-4c83-4b48-914c-5f89d3ad6cde
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1106821
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
1- 21 CFR 211.22(d)Procedures not in writing, fully followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Regeneron Pharmaceuticals Inc
12| Date | Classification | Office | Project area |
|---|---|---|---|
| March 22, 2024 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 16, 2024 | Not classified | New York District Office | |
| October 25, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 8, 2018 | Not classified | New York District Office | |
| October 5, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Regeneron Pharmaceuticals Inc
- FDA Inspection 1230565 - 2024-03-22
- FDA Inspection 1239760 - 2024-02-16
- FDA Inspection 1155063 - 2021-10-25
- FDA Inspection 1059234 - 2018-06-08
- FDA Inspection 1030807 - 2017-10-05
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.